Median ( 95 % confidence interval ) time to beginning of symptom relief at the primary attack location was 90 minutes ( 61-150 ) in rhC1INH-treated patients vs 152 minutes ( 93 , not estimable ) in placebo-treated patients ( P = .031 ) based on the TEQ and 75 minutes ( 60-105 ) vs 303 minutes ( 81-720 , P = .003 ) based on a VAS decrease of at least 20 mm .